Working to bring life-changing options to
redefine immunotherapy
COMPANY
Developing novel, validated solutions for infectious disease treatment
We are a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function.
Our product candidates include emricasan, CTS-2090, and other proprietary caspase inhibitors. Currently, we are developing emricasan for acute bacterial skin and skin structure infections (ABSSSI} as well evaluating its use for other infectious diseases.
Our difference
Non-antibiotic solution to prevent antibiotic resistance
Tested, known pathway of approval and known endpoints
Inflammation suppression that may cure infections faster
Management team
Decades of experience in bringing cell-based regenerative products from concept to market
